LAVERDIA-CA1
(verdinexor)

The first FDA Conditionally Approved Oral Tablet to Treat Lymphomain Dogs.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526

Novel Technology Targets Cancer at the Core

Using new SINE technology, LAVERDIA-CA1 (verdinexor) fights lymphoma where it starts - in the cell nucleus.

This is what a healthy cell without signs of lymphoma looks like

In dogs, a seemingly healthy cell can mutate rapidly into B-cell lymphoma, a fatal disease.

Or a more aggressive T-cell lymphoma, also fatal, and even harder to treat.

To fight lymphoma and other diseases, tumor suppressor proteins (TSPs) naturally live inside the nucleus of all cells

These tumor suppressors are responsible for preventing—suppressing—cancer from advancing, and for protecting healthy DNA.

In healthy cells, XPO1s transport molecules between the cell’s nucleus and cytoplasm to maintain balance and help the cell function.

But in cancer cells, XPO1s are produced in high volumes

A rapidly growing army of XPO1s seize tumor-suppressing TSPs...

...and shuttle them out of the cell nucleus, where they can no longer fight the advancement of cancer.

Without TSPs to protect the cell, cancer cells continue to grow and divide.

LAVERDIA-CA1 blocks XPO1s to battle canine lymphoma

LAVERDIA-CA1 selectively targets and binds to XPO1s. With LAVERDIA-CA1 in a blocking position, XPO1s can no longer grab TSPs and export them from the nucleus.

LAVERDIA-CA1 is the first and only canine cancer treatment that targets XPO1s.

TSPs build up inside the nucleus and the cancer cell undergoes apoptosis, or programmed cell death

LAVERDIA-CA1 kills lymphoma cells and slows the advance of cancer, giving you more time with your beloved pet.

Unlike most cancer treatments, LAVERDIA-CA1 generally spares healthy cells. When healthy cells are spared, negative side effects associated with cancer treatment are minimized.

LAVERDIA-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526


CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling.


IMPORTANT SAFETY INFORMATION: LAVERDIA-CA1 (verdinexor) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA-CA1. Children should not come in contact with the feces, urine, saliva, and vomit of treated dogs. View full product label for complete safety information. The most commonly reported adverse reactions in dogs include anorexia, weight loss, vomiting, diarrhea, and lethargy. Please see package insert or visit anivive.com for full prescribing information.

Loading 0%